Myriad Genetics | MYGN - Assets


Myriad Genetics reported $673.7M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Agilent USD 13.07B 252M Mar/2026
Becton, Dickinson and Co. USD 50.83B 4.01B Mar/2026
Bio-Rad Laboratories USD 9.79B 786.5M Mar/2026
Bruker USD 6.13B 110.7M Mar/2026
Danaher USD 83.54B 80M Mar/2026
Illumina USD 6.56B 85M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Mettler Toledo International USD 3.67B 43.73M Mar/2026
Myriad Genetics USD 673.7M 32.9M Mar/2026
OraSure Technologies USD 379.17M 24M Mar/2026
Pacific Biosciences Of California USD 782.36M 1.72M Mar/2026
Quest Diagnostics USD 16.67B 448M Mar/2026
Quidel USD 5.63B 140.6M Mar/2026
Repligen USD 2.93B 18.93M Mar/2026
Revvity USD 12B 171.82M Mar/2026
Standard Biotools USD 639.11M 71.36M Mar/2026
Thermo Fisher Scientific USD 113.28B 2.94B Mar/2026
Veracyte USD 1.44B 30.38M Mar/2026
Waters USD 24.53B 19.45B Mar/2026